Europe just enacted new requirements for device manufacturers to report anticipated product supply disruptions, and U.S. FDA wants the US Congress to follow suit: bit.ly/4jygqwn #MedTech

Everyone can appreciate a two for one deal. And MyStrategist is your one digital home for two of the #MedTech industry's most trusted publications. Take a break. Log in to access strategic medtech intelligence and stay informed today: bit.ly/3OnD8su

The biggest issue for #medtech execs isn’t regulatory—it’s #reimbursement. With CMS transparency concerns and complex Medicare Advantage navigation, how can companies bridge the gap? Experts weigh in on balancing innovation, coverage, and patient access: bit.ly/40muxfK

Will the U.S. follow Europe’s lead on device shortage reporting This compares the EU’s new Article 10a, which mandates proactive reporting, to the U.S.’s PHE-tied approach. Without broader mandates, the U.S. risks falling behind: bit.ly/4jygqwn #regulatory

Everyone can appreciate a two for one deal. And MyStrategist is your one digital home for two of the #medtech industry's most trusted publications. Take a break. Log in to MyStrategist.com to access strategic medtech intelligence: bit.ly/3OnD8su

Orphan devices—specialized #medicaldevices for rare conditions—face #regulatory hurdles under the EU MDR. While new guidance allows some flexibility, challenges remain. How should the EU address orphan device shortages?

What is the biggest #regulatory challenge your #medtech company faces?

Medtech CEOs, investors, and #reimbursement authorities share their views on the current state of #medtech coding, coverage, and payment in the US and the EU, and tell us how #AI and chatbots should be on product companies’ payment radar screens: bit.ly/3CyDgDO

ICYMI: Life Science Hub CEO Dr. Mark A. Turco discussed his career journey and vision for RI's life sciences sector with @MedTech Strategist. 💻Read the full article: mystrategist.com/medtech-strate…

Each month in Global Spotlight we provide #marketaccess facts from the country spotlighted on the cover of Market Pathways' print issue. The February 2025 cover features Brazilian Health Regulatory Agency (ANVISA) headquarters in Brasília: bit.ly/3QfyUEC

Join Gilde Healthcare's Janke Dittmer, Sofinnova Partners's Aantoine Papiernik, and @EndeavourVision's Alexander Schmitz at #InnovationDublin25 in the panel session "Scaling for Success: Strategies in Later-Stage and Growth Investing" during Day 1 from 12:35pm-1:15pm.

The future of medtech is taking shape at MedTech Strategist | MedTech's Most Trusted Source #InnovationDB25. From April 29–May 1, join 300+ #medtech leaders, investors, and innovators for exclusive insights, strategic networking, and in-depth industry discussions. Register today: bit.ly/42UeKaX

How are VCs adapting to an evolving #medtech market? At #InnovationDublin25, leading investors discuss strategies, challenges, and trends in raising new funds to fuel the next wave of medical technology innovation.

Explore the barriers and opportunities learn directly from key decision-makers and read stories of companies that are persevering along every pathways of the #medtech market with Market Pathways | MedTech Regulatory & Policy. Learn why you need us for your market access strategy: bit.ly/46Q3lIz

#Robotics pioneer Intuitive continues to be the dominant player with greater than 80% market share, nearly 10,000 da Vinci systems placed, and revenue growth in the mid to high teens, more than 20 years after it introduced the da Vinci robot: bit.ly/4hg6bum

Federal agencies including #FDA have retreated from various forms of public and stakeholder engagement during the opening weeks of the Trump administration. In #medtech, that’s starting to impact global standards development efforts and more: bit.ly/3F4L0OL

Ortho, spine, and #medtech are thriving, but elective procedures face economic and political uncertainties. MedTech Strategist | MedTech's Most Trusted Source talks with BTIG's Ryan Zimmerman on the 2025 outlook and what he hopes to learn at AAOS 2025 (March 10-14, San Diego): bit.ly/3FcPUt1

NEW EP. of Market Pathways | MedTech Regulatory & Policy Podcast: Following a robust 2024, the medical device sector continues to thrive in 2025 and remains somewhat insulated from dramatic shifts in #healthcare policies, at least in the short term: bit.ly/42nb0hG

Be the expert in the room. Stay ahead of the curve in #medtech regulatory, reimbursement, and policy with Pathways' Document Depot: bit.ly/4kCLqMi

Medtech has been accelerating innovation in product development with a record 124 new #devices approved by the FDA in 2023. Yet, this speed is not matched in #medtech trials, which can take up to seven years to complete. By Nicole Bongers, Veeva Systems: bit.ly/3FnXkJU